Is Victoza Still Prescribed After Ozempic's Launch?
Yes, Victoza (liraglutide) remains in use despite Ozempic (semaglutide) availability since 2017. Both are GLP-1 receptor agonists for type 2 diabetes, but Victoza holds a 21% U.S. market share versus Ozempic's 45% as of mid-2024, per prescription data.[1] Novo Nordisk continues manufacturing and marketing Victoza, with over 1 million U.S. prescriptions in 2023.[2]
Why Do Doctors Still Choose Victoza Over Ozempic?
Victoza offers once-daily dosing, suiting patients who dislike Ozempic's weekly injections. It's FDA-approved for kids aged 10+ with type 2 diabetes, unlike adult-only Ozempic. Cost favors Victoza at $300–$400/month without insurance versus Ozempic's $900+, though copay cards narrow gaps.[3] Some prefer Victoza's established safety profile from longer use (approved 2010).[1]
How Do Ozempic and Victoza Compare Head-to-Head?
| Aspect | Victoza | Ozempic |
|--------|---------|---------|
| Dosing | Daily injection | Weekly injection |
| A1C Reduction | 1.0–1.5% | 1.5–2.0% |
| Weight Loss | 5–10 lbs average | 10–15 lbs average |
| CV Risk Reduction | Proven (LEADER trial) | Proven (SUSTAIN trials) |
| Off-Label Weight Loss Use | Less common | Widespread (despite label limits) |
| Patent Expiry | 2023 (U.S.) | 2032 (U.S.)[4] |
Ozempic edges out on efficacy, but Victoza matches on heart benefits and costs less amid shortages.[1][5]
What Happens with Victoza Shortages or Supply Issues?
Victoza faced U.S. shortages in 2023–2024 due to demand surges, pushing some to Ozempic or alternatives like Trulicity. Supplies stabilized by late 2024, but Novo warns of intermittent issues.[6] Patients report easier access to Victoza pens now.
Can Patients Switch from Victoza to Ozempic Easily?
Switching works but requires doctor oversight—both cause nausea initially, though Ozempic's lasts longer for some. No washout needed; start low-dose Ozempic post-Victoza. About 20% of Victoza users switched to Ozempic by 2023, often for better weight control.[2]
When Does Victoza Face Biosimilar Competition?
Victoza's key U.S. patents expired in 2023, opening doors for generics/biosimilars, but none launched by 2024 due to formulation patents lasting to 2026 and ongoing litigation.[4] First copies expected 2025–2027, potentially dropping prices 30–50%.[7]
Are There Patient Concerns or Side Effects Driving Choices?
Common complaints mirror both drugs: nausea (20–40%), GI issues, rare pancreatitis. Victoza users note less "Ozempic face" (facial sagging from rapid weight loss). Thyroid cancer warnings apply to both; avoid if family history.[5] Off-label weight loss boosts Ozempic demand, but Victoza sees steady diabetes use.
[1]: IQVIA National Prescription Audit, 2024.
[2]: Novo Nordisk Annual Report, 2023.
[3]: GoodRx pricing data, Oct 2024.
[4]: DrugPatentWatch.com (liraglutide patents).
[5]: FDA Labels, Victoza vs. Ozempic.
[6]: FDA Drug Shortages Database, 2024.
[7]: Evaluate Pharma forecasts, 2024.